PNCB's third edition of all new in-depth psychopharmacology CE includes 12 journal articles for your references. Whether you treat and prescribe—or manage other care for youth taking these medications under another provider's care—this is a must-take module given the prevalence of behavioral and mental health conditions among children and teens. Topics covered:
Treatment guidelines for ADHD, anxiety, and care of adolescents with depression in the primary care setting (recently updated ADHD, anxiety, & depression management guidelines)
Recommendations and emerging evidence for treatment of children and adolescents with ADHD, depression, and autism spectrum disorder and comorbid mental health diagnoses including:
Management of depression in children and adolescents with medical illness
Recommendations and available evidence for pharmacologic treatment for children and adolescents with bipolar disorder, obsessive-compulsive disorder, agitation, and delirium
Adverse effects, FDA “black box warnings,” and medication interactions for psychopharmacologic agents used for treatment of children and adolescents with mental health diagnoses
Monitoring for and treatment of adverse effects associated with psychopharmacologic agents
For APRNs, RNs, or those familiar with pediatric pharmacology. View Content Outline
7.5 pharmacology contact hours accredited by NAPNAP (7.5 related to psychopharmacology) (1.25 related to controlled substances).
Answers are due 150 days from order process date.
41 questions.
What references are included?
12 online PDF articles from 8 journals (a $300+ value) to support answering all 41 questions.
Sample Question
Q. A school-aged child diagnosed with social anxiety disorder is currently taking several medications for previously diagnosed medical conditions. When selecting an SSRI, which has a lower risk for potential drug interactions? A. escitalopram B. fluvoxamine C. paroxetine D. sertraline